CXCL8 and non-small cell lung carcinoma: NSCLC therapy is limited by chemoresistance, which is mediated by multiple mechanisms, including mutation or loss of molecular targets, induction of autophagy, increased repair of DNA damage, inactivation of apoptosis, tumor heterogeneity and IL-6 and IL-8 release (4, 5).